Media headlines about Apollo Endosurgery (NASDAQ:APEN) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apollo Endosurgery earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.1955131413118 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern’s scoring:
- Financial Review: Apollo Endosurgery (APEN) vs. iRadimed Corporation (IRMD) (americanbankingnews.com)
- Reviewing Apollo Endosurgery (APEN) & Tactile Systems Technology (TCMD) (americanbankingnews.com)
- Comparing Penumbra (PEN) and Apollo Endosurgery (APEN) (americanbankingnews.com)
- Financial Contrast: Penumbra (PEN) & Apollo Endosurgery (APEN) (americanbankingnews.com)
- Reviewing iRadimed Corporation (IRMD) & Apollo Endosurgery (APEN) (americanbankingnews.com)
Apollo Endosurgery (NASDAQ:APEN) last posted its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.40). The business had revenue of $17.14 million for the quarter. Apollo Endosurgery had a negative return on equity of 142.98% and a negative net margin of 81.59%.
Several analysts have recently issued reports on the stock. Northland Securities assumed coverage on shares of Apollo Endosurgery in a research report on Tuesday, September 26th. They set an “outperform” rating and a $12.00 target price on the stock. Craig Hallum assumed coverage on shares of Apollo Endosurgery in a research report on Monday, July 24th. They set a “buy” rating and a $11.00 target price on the stock. Roth Capital assumed coverage on shares of Apollo Endosurgery in a research report on Wednesday, August 2nd. They set a “buy” rating and a $10.00 target price on the stock. Finally, ValuEngine cut shares of Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd.
In related news, major shareholder Holdings A/S Novo sold 50,130 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $6.90, for a total transaction of $345,897.00. Following the transaction, the insider now directly owns 1,334,772 shares in the company, valued at $9,209,926.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sciences L. P. Ptv II purchased 1,090,909 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average price of $5.50 per share, for a total transaction of $5,999,999.50. The disclosure for this purchase can be found here. Insiders have purchased 1,277,271 shares of company stock worth $7,024,991 over the last 90 days. 74.20% of the stock is currently owned by company insiders.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.